Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly

This page shows the latest Eli Lilly news and features for those working in and with pharma, biotech and healthcare.

Lilly invests in antibody oligonucleotides conjugates with Avidity deal

Lilly invests in antibody oligonucleotides conjugates with Avidity deal

Companies to develop new immonology medicines. Eli Lilly is aiming to develop new immunology drugs based on DNA/RNA molecules, and has enlisted the help of antibody oligonucleotide conjugates (AOC) specialist ... Lilly's extensive research, development,

Latest news

More from news
Approximately 78 fully matching, plus 547 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Since 2012, AC Immune has partnered tau assets with Roche’s Genentech, Johnson &Johnson and Eli Lilly. ... Sosei Heptares’ work on M1 falls into the latter category. Eli Lilly took an M1 agonist, xanomeline, into phase 3 in the 1990s and emerged with

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    EPAD combines knowledge and expertise from 39 European partner organisations across multiple sectors, including most of the big pharma companies involved in Alzheimer’s research (including Amgen, Janssen and Lilly, among ... Last month, Johnson

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Developed in partnership with Eli Lilly, it has already presented positive phase 3 results, with more expected in the first half of 2019, with filings expected shortly afterwards.

  • The good, the bad and the ugly The good, the bad and the ugly

    Pfizer ultimately lost. Patent expiries also led to large declines in CNS sales at Teva (-17%) and Eli Lilly (-27.5%).

  • Patient involvement in health technology assessment Patient involvement in health technology assessment

    David Grainger, Global Public Policy, Eli Lilly: “In terms of supporting patient participation, some jurisdictions limit the communication from industry to patients to just the fact that a new technology is

More from intelligence
Approximately 3 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 29 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics